Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the compensation committee of the company's board of directors granted nine new employees options to purchase a total of 34,000 shares of the company's common stock at an exercise price per share of $17.
RCUS Ratings Summary
RCUS Quant Ranking